Dariohealth Corp Stock Price, News & Analysis

DarioHealth (NASDAQ: DRIO) has secured a partnership with a major U.S. healthcare research and medical institution, marking its second significant healthcare employer agreement. The partnership, which is already generating recurring revenue in 2025, involves the implementation of Dario's complete suite of AI-powered digital health solutions.

The institution will deploy Dario Health, Dario Mind, and Dario Move platforms, covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company's solutions have demonstrated above-average engagement rates and significant improvements in health metrics, including reductions in A1c, blood pressure, and MSK-related pain.

DarioHealth (DRIO) reported strong financial results for Q4 and full-year 2024, with annual revenue increasing 32.9% to $27.0 million. The company's B2B2C channel showed remarkable growth, with recurring revenues rising 300% year-over-year. Q4 2024 revenue reached $7.6 million, up 110% from Q4 2023.

Key highlights include completion of a $25.6 million equity financing, resulting in a $34.5 million proforma cash balance. Operating loss decreased by 35% to $11.7 million (GAAP) in Q4 2024. The company added 36 new employer and health plan clients in 2024, bringing total client base to 83, with a projected 50% net client growth in 2025.

Following the Twill acquisition, Dario expanded its AI-powered platform to support five chronic conditions. The company expects to achieve operational cash flow breakeven by end of 2025, supported by an anticipated 20% reduction in operating expenses. Gross margins exceeded 80% in the B2B2C business over the past three quarters.

DarioHealth Corp. (Nasdaq: DRIO) has announced a strategic collaboration with Rula Health to expand its behavioral health offerings through access to over 15,000 providers nationwide. The partnership aims to enhance Dario's B2B2C sales growth by integrating Rula's extensive provider network, which covers over 120 million commercial lives through major insurance networks.

The collaboration creates an 'easy button' solution for employers implementing behavioral health support within existing benefits structures. The integrated solution combines Dario's digital health capabilities, including AI-driven engagement and digital coaching, with Rula's provider network to deliver comprehensive mental health support.

This strategic arrangement is expected to accelerate Dario's presence in the employer channel while increasing visibility through Rula's partner base. The partnership focuses on delivering personalized, evidence-based behavioral health support and seamless access to licensed therapists.

DarioHealth Corp. (NASDAQ: DRIO) has secured a significant contract with a major healthcare system, marking its entry into the healthcare provider employer market in Q1 2025. This agreement contributes to Dario's 15 new client signings targeted for 2025.

The partnership will provide AI-powered chronic care management solutions to the healthcare system's employees, focusing on conditions including diabetes, hypertension, musculoskeletal pain, and mental health. Clinical studies demonstrate Dario's effectiveness, showing a 2.3-point reduction in A1C levels for diabetes patients and 28-30% decrease in anxiety and depression over eight weeks through its Dario Mind platform.

This milestone represents a breakthrough in healthcare system adoption of digital health solutions, traditionally a slower-moving sector due to reimbursement challenges and provider skepticism. The partnership validates Dario's approach to combining AI-driven personalization with user-friendly interfaces to bridge the gap between traditional care models and digital interventions.

DarioHealth Corp (Nasdaq: DRIO), a digital health market leader, has scheduled its Q4 and full-year 2024 financial results announcement for Monday, March 10th, 2025, before market opening. The company will host a conference call and webcast at 8:30 AM ET, featuring CEO Erez Raphael and CCO Steven Nelson.

Participants can join via phone using domestic (1-800-717-1738) or international (1-646-307-1865) dial-in numbers, or through the Call me™ link available 15 minutes before the event. A webcast option is also available. The earnings call replay will be accessible until March 24th, 2025, using replay passcode 1134608.

DarioHealth (Nasdaq: DRIO) has appointed Lawrence (Larry) B. Leisure to its Board of Directors, bringing four decades of healthcare leadership experience to the AI-driven digital health solutions company. Leisure's extensive background includes leadership roles at prominent organizations such as:

• Towers Perrin as National Practice Leader
• Senior Partner at PricewaterhouseCoopers
• Managing Partner at Accenture
• Kaiser Foundation Health Plan
• UnitedHealth Group's OptumInsight

As co-founder of Chicago Pacific Founders and the Employer Health Innovation Roundtable, Leisure brings expertise in healthcare technology, managed care, and value-based care models. He currently serves as Chairman of the UCSF Rosenman Institute and holds advisory positions at UCLA Anderson School of Management and Stanford University's Mussalem Center for BIODESIGN.

DarioHealth (DRIO) has secured a new agreement with a Blue Cross Blue Shield (BCBS) health plan, expanding its presence in the health plan market. The program, launched in January 2025, integrates Dario's AI-driven health coaching platform, offering comprehensive cardiometabolic digital health solutions for diabetes, hypertension, and weight management.

The agreement is already contributing to the Company's annual recurring revenue (ARR) in Q1 2025, with expectations for further expansion throughout the year. This marks Dario's ninth health plan partnership, spanning both regional and national payers. The collaboration strengthens Dario's position in the cardiometabolic disease market, which is projected to surpass $1.2 trillion by 2033.

DarioHealth Corp. (NASDAQ: DRIO) has announced a new partnership with a large regional health plan, an affiliate of a top 10 national health plan, expanding its presence in the digital health market. The agreement, effective January 2025, integrates Dario's AI-driven health coaching platform into the health plan's member services.

The partnership focuses on comprehensive cardiometabolic digital health solutions, including programs for diabetes, hypertension, and weight management. This marks Dario's ninth health plan partnership, contributing to the company's annual recurring revenue (ARR) in Q1 2025, with potential for further expansion throughout the year.

The agreement positions Dario strategically in the cardiometabolic disease market, which is projected to exceed $1.2 trillion by 2033. The company's AI-driven platform continues to gain traction among payers seeking scalable, data-driven solutions that deliver measurable health improvements and cost efficiencies.

DarioHealth (DRIO) is emerging as a significant player in digital health, leveraging over 13 billion real-world data points to address multiple chronic care conditions. The company's integrated platform covers diabetes, hypertension, behavioral health, musculoskeletal pain, weight management, and maternal health.

Key achievements include a 111% year-over-year revenue growth to $7.42 million in Q3 2024, and a recent $25.6 million private placement bringing their proforma cash balance to $40.6 million. The company aims to achieve operational cash flow positivity by the end of H1 2025, supported by a 38% reduction in operating expenses by Q1 2025.

DarioHealth has expanded into the GLP-1 weight-loss solutions market, partnering with MediOrbis to offer end-to-end solutions. The company has secured contracts with 12 Fortune 500 companies and established partnerships with major insurers and pharmaceutical companies. Their platform has demonstrated significant clinical improvements, including a 58% reduction in hyperglycemic events and a 59% reduction in anxiety symptoms.